[Treatment of contusion of moderate severity in children in outpatient clinics].
Level 3 - non-randomized controlled study
Controlled clinical trial without documented randomization in the abstract
PubMed 32323940 · doi:10.17116/jnevro202012003129
What was done
Seventy-four children aged 6 to 13 years with moderate brain contusion from traumatic brain injury were evaluated in an outpatient clinic setting. The intervention group received standard therapy plus cortexin, while the control group received standard therapy alone. Baseline and 30-day post-treatment evaluations included neurological and ophthalmological examinations, brain CT scans, electroencephalography (EEG), and psychological testing.
What was found
Both groups showed improvement at 30 days. Compared with the control group, the cortexin group demonstrated significantly greater reductions in subjective symptoms (p < 0.01) and focal neurological symptoms (p < 0.001), greater resolution of hypertensive-hydrocephalic signs (p < 0.05), absence of acute EEG waves during physical activity, and age-appropriate cortical electrogenesis. The abstract reports no baseline values, point estimates, confidence intervals, or specific numerical cognitive test scores.
Why it matters
This study provides preliminary clinical evidence suggesting that adding cortexin to standard outpatient care may assist short-term symptom reduction and EEG normalization after moderate pediatric brain contusions.
Limits
Randomization, allocation concealment, and blinding were not documented in the abstract, introducing substantial risk of bias. Individual group sample sizes, medication dosages, baseline balance, and exact numerical outcome values are not reported. The follow-up period was limited to 30 days with no long-term functional follow-up.
Cited by
- supports Russian studies have evaluated Cortexin and Cerebrolysin for traumatic brain injury (TBI).